- Home
- PBYI vs RGC Comparison
PBYI vs RGC Comparison
Compare PBYI & RGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- RGC
- Stock Information
- Founded
- PBYI 2010
- RGC 2014
- Country
- PBYI United States
- RGC Hong Kong
- Employees
- PBYI N/A
- RGC N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- RGC Medicinal Chemicals and Botanical Products
- Sector
- PBYI Health Care
- RGC Health Care
- Exchange
- PBYI Nasdaq
- RGC Nasdaq
- Market Cap
- PBYI 167.3M
- RGC 38.6B
- IPO Year
- PBYI N/A
- RGC 2021
- Fundamental
- Price
- PBYI $3.38
- RGC $16.49
- Analyst Decision
- PBYI Strong Buy
- RGC
- Analyst Count
- PBYI 1
- RGC 0
- Target Price
- PBYI $7.00
- RGC N/A
- AVG Volume (30 Days)
- PBYI 379.0K
- RGC 1.6M
- Earning Date
- PBYI 07-31-2025
- RGC 06-30-2025
- Dividend Yield
- PBYI N/A
- RGC N/A
- EPS Growth
- PBYI 143.51
- RGC N/A
- EPS
- PBYI 0.77
- RGC N/A
- Revenue
- PBYI $232,709,000.00
- RGC N/A
- Revenue This Year
- PBYI N/A
- RGC N/A
- Revenue Next Year
- PBYI N/A
- RGC N/A
- P/E Ratio
- PBYI $4.36
- RGC N/A
- Revenue Growth
- PBYI 2.68
- RGC N/A
- 52 Week Low
- PBYI $2.23
- RGC $0.08
- 52 Week High
- PBYI $4.13
- RGC $83.60
- Technical
- Relative Strength Index (RSI)
- PBYI 48.53
- RGC 48.41
- Support Level
- PBYI $3.25
- RGC $19.80
- Resistance Level
- PBYI $3.39
- RGC $34.58
- Average True Range (ATR)
- PBYI 0.15
- RGC 11.93
- MACD
- PBYI -0.03
- RGC -1.18
- Stochastic Oscillator
- PBYI 22.22
- RGC 10.50
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.